Structural Genomics Consortium (SGC)

See the following -

For UNC Scientists, Open Source is the Way Forward

Fibrodysplasia ossificans progressiva—more commonly called stone man's syndrome—is the result of a rare mutation, an anomaly in the way certain enzymes called kinases spur protein synthesis. Someone with stone man's syndrome has hyperactive kinases that catalyze more bone production than they should. The body's natural repair mechanisms malfunction, and they replace soft tissue with deposits of solid bone. Joints freeze. The body becomes a prison. But scientists know they can manipulate those kinases to combat the disease. And chemical biologists at the University of North Carolina are leading an open source effort to unlock the secrets of kinase activity—secrets they say could pioneer a new generation of drug discovery...

Open-access R&D for Drug Industry

Reuters | Dawn.com | September 29, 2011

LONDON: Drug companies are learning how to share. In a bid to save both time and money, some of the industry’s biggest names are experimenting with new ways to pool early-stage research, effectively taking a leaf out of the “open-source” manual that gave the world Linux software. Read More »

The Ontario Institute for Cancer Research and the Structural Genomics Consortium develop and give away new drug-like molecule to help crowd-source cancer research.

Press Release | Ontario Institute for Cancer Research, Structural Genomics Consortium | September 3, 2015

Through a novel open source approach the molecule has been made freely available to the cancer research community to help discover new therapeutic strategies for cancer patients sooner...Researchers from the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC) at the MaRS Discovery District in Toronto have developed a new drug prototype called OICR-9429 and made it freely available to the research community. Already research conducted by international groups using OICR-9429 has shown it to be effective in stopping cancer cell growth in breast cancer cell lines and a specific subtype of leukemia cells.

Read More »